Kim, Jae Hui
Sagong, Min
Woo, Se Joon
Kim, Yu Cheol
Cho, Heeyoon
Lee, Young Hoon
Byon, Iksoo
Jo, Young Joon
Chin, Hee Seung
Lee, Youkyung
Chae, Jae Eun
Kang, Se Woong
Article History
Received: 21 March 2022
Accepted: 5 August 2022
First Online: 19 August 2022
Competing interests
: Jae Hui Kim reports grants from Novartis and Bayer. Min Sagong reports honoraria from Allergan, Bayer, Novartis, and Roche for lecture fees, consultancy, and board membership and reports research grants from Allergan, Bayer, and Novartis. Se Joon Woo is a consultant of Samsung Bioepis, Curacle, Novelty Nobility, Sometech, Philophos, Janssen, and Allergan; reports grants from Samsung Bioepis, Curacle, and Alteogen; reports lecture fees from Novartis, Bayer, Allergan/AbbVie, and Santen; and owns equity of RetiMark and Panolos Bioscience. Yu Cheol Kim is a consultant for Novartis and Bayer; received honoraria from Allergan, Bayer, and Novartis; and research grants from Chong Kun Dang Pharm., SCD Pharm., Bayer, and Novartis. Heeyoon Cho reports lecture fees and consultancy from Allergan, Bayer, and Novartis. Young Hoon Lee has no financial disclosures. Iksoo Byon is a consultant/advisor for Novartis, Bayer, and AIinsight Inc and reports grants from Novartis and Busan Technopark. Young Joon Jo reports grants from Bayer and Novartis. Hee Seung Chin has no financial disclosures.Youkyung Lee is a full-time employee of Novartis Korea Ltd. Jae Eun Chae is a full-time employee of LSK Global Pharma Services, Korea. Se Woong Kang has served on advisory boards for Novartis, Bayer, Allergan, Alcon, and Samchundang and has received consultancy fees and payments for lectures from these companies.